Literature DB >> 28364257

[Geriatric assessment of patients with hematological neoplasms].

Benedikt Hofer1, Laurenz Nagl2, Florian Hofer2, Reinhard Stauder3.   

Abstract

Hematological malignancies are typical diseases of the elderly. The aging of the population in the Western World results in a significant increase in the number of elderly patients with hematological malignant diseases. This has important consequences for medicine. One consequence of this development is that the need for tools for the evaluation of both functional and global status of the elderly increases. The use of these tools enables the hematologist to better stratify the patients, to individualize therapy better, to possibly modify therapy in order to improve implementation of supportive measures and interventions, to minimize toxicity and side effects and ultimately to tailor the treatment to the individual patient. Several tools are available for geriatric assessment (GA) and there is strong evidence that an effective GA can detect previously unknown problems. The targeted intervention improves the prognosis and compliance of therapy in elderly patients with hematological malignant diseases.

Entities:  

Keywords:  Chemotherapy; Interdisciplinary health team; Myelodysplastic syndrome; Toxicity; Vulnerable populations

Mesh:

Year:  2017        PMID: 28364257     DOI: 10.1007/s00391-017-1222-6

Source DB:  PubMed          Journal:  Z Gerontol Geriatr        ISSN: 0948-6704            Impact factor:   1.281


  23 in total

1.  Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study.

Authors:  Arti Hurria; Kayo Togawa; Supriya G Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Stuart M Lichtman; Ajeet Gajra; Smita Bhatia; Vani Katheria; Shira Klapper; Kurt Hansen; Rupal Ramani; Mark Lachs; F Lennie Wong; William P Tew
Journal:  J Clin Oncol       Date:  2011-08-01       Impact factor: 44.544

2.  Aging and blood disorders: new perspectives, new challenges.

Authors:  Dominique Bron; Lionel Ades; Tamas Fulop; Valentin Goede; Reinhard Stauder
Journal:  Haematologica       Date:  2015-04       Impact factor: 9.941

3.  The abbreviated comprehensive geriatric assessment (aCGA): a retrospective analysis.

Authors:  Janine A Overcash; Jason Beckstead; Martine Extermann; Sara Cobb
Journal:  Crit Rev Oncol Hematol       Date:  2005-05       Impact factor: 6.312

Review 4.  EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.

Authors:  C Bokemeyer; M S Aapro; A Courdi; J Foubert; H Link; A Osterborg; L Repetto; P Soubeyran
Journal:  Eur J Cancer       Date:  2006-12-19       Impact factor: 9.162

Review 5.  Geriatric oncology: a clinical approach to the older patient with cancer.

Authors:  L Repetto; A Venturino; L Fratino; D Serraino; G Troisi; W Gianni; M Pietropaolo
Journal:  Eur J Cancer       Date:  2003-05       Impact factor: 9.162

6.  EORTC elderly task force position paper: approach to the older cancer patient.

Authors:  A G Pallis; C Fortpied; U Wedding; M C Van Nes; B Penninckx; A Ring; D Lacombe; S Monfardini; P Scalliet; H Wildiers
Journal:  Eur J Cancer       Date:  2010-03-12       Impact factor: 9.162

7.  A specialized home care intervention improves survival among older post-surgical cancer patients.

Authors:  R McCorkle; N E Strumpf; I F Nuamah; D C Adler; M E Cooley; C Jepson; E J Lusk; M Torosian
Journal:  J Am Geriatr Soc       Date:  2000-12       Impact factor: 5.562

Review 8.  Vulnerability in the elderly: frailty.

Authors:  Joris P J Slaets
Journal:  Med Clin North Am       Date:  2006-07       Impact factor: 5.456

9.  Effect of nurse case management on the treatment of older women with breast cancer.

Authors:  James S Goodwin; Shiva Satish; Elizabeth T Anderson; Ann B Nattinger; Jean L Freeman
Journal:  J Am Geriatr Soc       Date:  2003-09       Impact factor: 5.562

10.  Old or frail: what tells us more?

Authors:  Hanneke Schuurmans; Nardi Steverink; Siegwart Lindenberg; Nynke Frieswijk; Joris P J Slaets
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2004-09       Impact factor: 6.053

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.